mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Inclusion Criteria: 1. signed informed consent form; 2. confirmed as colorectal cancer by pathology, and the stage is IIIB /IIIC according to the NCCN guidelines; 3. patients with primary colorectal cancer; 4. radical resection of colon cancer (CME) or radical resection of rectal cancer (TME) has done; 5. 3\~4 weeks after radical resection ; 6. patients did not receive any radiotherapy and chemotherapy before operation Exclusion Criteria: 1. emergency operation for colorectal cancer patients; 2. the situation after operation can not tolerance for systemic adjuvant chemotherapy (hemoglobin \<95g/L, white blood cell \<3 \* 109/L, granulocyte \<1.5 \* 109/L and platelet \<75 \* 109/L, bilirubin\>2.5N, alanine aminotransferase \>2.5N, alkaline phosphatase \>2.5N, urea nitrogen \>2.5N, creatinine \>2.5N, proteinuria, hematuria, temperature of \>38 degree); 3. serious diseases such as cardiac insufficiency, respiratory insufficiency, liver and kidney dysfunction, serious blood diseases; 4. patients participated in other clinical trials at the same time; 5. pregnant or perinatal women; 6. combined with other malignant tumors; 7. a history of neuropsychiatric disorders; 8. patients have used anti angiogenesis targeted drugs (such as bevacizumab, cetuximab); 9. patients had a history of severe trauma within 4 weeks before admission; 10. allergic to chemotherapy drugs or apatinib; 11. active bleeding, ulcers, intestinal perforation, intestinal obstruction, hypertension